Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).

Li G, Du X, Vass WC, Papageorge AG, Lowy DR, Qian X.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17129-34. doi: 10.1073/pnas.1112122108. Epub 2011 Oct 3.

2.

CDK5 is a major regulator of the tumor suppressor DLC1.

Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, Lowy DR.

J Cell Biol. 2014 Dec 8;207(5):627-42. doi: 10.1083/jcb.201405105. Epub 2014 Dec 1.

3.

Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Chen L, Liu C, Ko FC, Xu N, Ng IO, Yam JW, Zhu G.

J Biol Chem. 2012 Jul 27;287(31):26104-14. doi: 10.1074/jbc.M112.360206. Epub 2012 May 29.

4.

Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.

Ravi A, Kaushik S, Ravichandran A, Pan CQ, Low BC.

J Biol Chem. 2015 Feb 13;290(7):4149-62. doi: 10.1074/jbc.M114.616839. Epub 2014 Dec 18.

5.

Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Chan LK, Ko FC, Ng IO, Yam JW.

PLoS One. 2009;4(5):e5572. doi: 10.1371/journal.pone.0005572. Epub 2009 May 15.

6.

Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG, Lowy DR.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):9012-7. Epub 2007 May 15.

7.

Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.

Cao X, Voss C, Zhao B, Kaneko T, Li SS.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1455-60. doi: 10.1073/pnas.1114368109. Epub 2012 Jan 17. Erratum in: Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4708.

8.

Concerted modulation of paxillin dynamics at focal adhesions by Deleted in Liver Cancer-1 and focal adhesion kinase during early cell spreading.

Kaushik S, Ravi A, Hameed FM, Low BC.

Cytoskeleton (Hoboken). 2014 Dec;71(12):677-94. doi: 10.1002/cm.21201. Epub 2015 Jan 31.

PMID:
25448629
9.

Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.

Yam JW, Ko FC, Chan CY, Jin DY, Ng IO.

Cancer Res. 2006 Sep 1;66(17):8367-72.

10.

START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2.

Kawai K, Kitamura SY, Maehira K, Seike J, Yagisawa H.

Adv Enzyme Regul. 2010;50(1):202-15. doi: 10.1016/j.advenzreg.2009.10.013. Epub 2009 Nov 4. No abstract available.

PMID:
19895840
11.

Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3.

Shi H, Liu H, Zhao G.

Mol Biol Rep. 2012 Oct;39(10):9299-306. doi: 10.1007/s11033-012-1724-7. Epub 2012 Jul 4.

PMID:
22760257
12.

Tensin1 positively regulates RhoA activity through its interaction with DLC1.

Shih YP, Sun P, Wang A, Lo SH.

Biochim Biophys Acta. 2015 Dec;1853(12):3258-65. doi: 10.1016/j.bbamcr.2015.09.028. Epub 2015 Sep 28.

13.

p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities.

Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC.

Oncogene. 2009 Mar 19;28(11):1401-9. doi: 10.1038/onc.2008.498. Epub 2009 Jan 19.

14.

DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.

Scholz RP, Regner J, Theil A, Erlmann P, Holeiter G, Jähne R, Schmid S, Hausser A, Olayioye MA.

J Cell Sci. 2009 Jan 1;122(Pt 1):92-102. doi: 10.1242/jcs.036251. Epub 2008 Dec 9.

15.

Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.

Shih YP, Takada Y, Lo SH.

Mol Cancer Res. 2012 Jan;10(1):34-9. doi: 10.1158/1541-7786.MCR-11-0450. Epub 2011 Nov 7.

16.

[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].

Feng Y, Zhou HX, Li JH, Li ZY, Cheng WG, Jin ML, He L.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Aug;31(8):1448-51. Chinese.

18.

Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.

Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY, Ng IO.

Cancer Res. 2005 Oct 1;65(19):8861-8.

19.

The NPIY motif in the integrin beta1 tail dictates the requirement for talin-1 in outside-in signaling.

Nieves B, Jones CW, Ward R, Ohta Y, Reverte CG, LaFlamme SE.

J Cell Sci. 2010 Apr 15;123(Pt 8):1216-26. doi: 10.1242/jcs.056549. Epub 2010 Mar 23.

20.

Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.

Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR.

Cancer Res. 2012 Sep 1;72(17):4405-16. doi: 10.1158/0008-5472.CAN-12-0777. Epub 2012 Jun 12.

Supplemental Content

Support Center